基于SUV4.0分割阈值的代谢肿瘤体积对1960例淋巴瘤患者预后影响:来自前瞻性LYSA试验
研究比较了SUV4.0与41%SUVmax两种分割阈值测量的总代谢肿瘤体积(TMTV)在淋巴瘤中的预后价值,纳入1960例弥漫大B细胞淋巴瘤、滤泡性淋巴瘤和霍奇金淋巴瘤患者的基线PET/CT。两种方法预测无进展生存期(PFS)的能力相当,置信区间重叠;在90百分位TMTV值时,两方法预测的7年PFS接近。作者认为SUV4.0阈值可常规采用,尤其在弥漫大B细胞淋巴瘤亚型。
要点
- TMTV4.0与TMTV41%的相关性在DLBCL为ρ=0.90,FL为ρ=0.65,HL为ρ=0.60。
- 两方法预测PFS的置信区间重叠,90百分位TMTV值时7年PFS预测值接近。
- 仅少数患者两方法预测PFS偏差>10%:DLBCL 2.33%、FL 6.51%、HL 1%。
核心结论
- SUV4.0阈值测量的TMTV提供的PFS预测与41%SUVmax方法相当,支持其常规采用,尤其在弥漫大B细胞淋巴瘤亚型。
研究设计与样本
- 研究收集了1960例弥漫大B细胞淋巴瘤、滤泡性淋巴瘤和霍奇金淋巴瘤患者的基线PET/CT扫描,来自前瞻性LYSA试验。
- 对感兴趣区进行半自动预选后,应用两种分割阈值:41%SUVmax(TMTV41%)和SUV>4.0(TMTV4.0)。
主要发现
- TMTV4.0与TMTV41%的相关性:DLBCL ρ=0.90,FL ρ=0.65,HL ρ=0.60。
- SUVmax、SUVpeak、Dmax和Dbulk特征与两种TMTV方法的相关性均强,无论淋巴瘤亚型,ρ>0.95。
- 在90百分位TMTV值,预测7年PFS:DLBCL患者TMTV4.0为51.13% vs TMTV41%为49.7%;FL患者45.5% vs 39.8%;HL患者82.6% vs 80.5%。
- 两方法预测PFS偏差>10%的患者比例:DLBCL 2.33%,FL 6.51%,HL 1%。
关键数值与推荐
- TMTV4.0与TMTV41%相关性:DLBCL ρ=0.90,FL ρ=0.65,HL ρ=0.60。
- 90百分位TMTV值时预测7年PFS:DLBCL TMTV4.0 51.13% vs TMTV41% 49.7%;FL 45.5% vs 39.8%;HL 82.6% vs 80.5%。
- 两方法预测PFS偏差>10%的患者比例:DLBCL 2.33%,FL 6.51%,HL 1%。
临床怎么用
- 作者认为SUV4.0阈值测量的TMTV支持其常规采用,尤其在弥漫大B细胞淋巴瘤亚型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study compared the prognostic value of total metabolic tumor volume (TMTV) in lymphoma measured with the recently proposed SUV4.0 segmentation threshold versus the 41% SUVmax across LYSA trials and its impact on intensity and dissemination PET features. METHODS: A total of 1960 baseline PET/CT scans of Diffuse Large B cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin lymphoma (HL) patients were collected. After a semi-automatic preselection of region of interest, two different segmentation threshold were applied: 41% SUVmax (TMTV41%) and SUV > 4.0 (TMTV4.0). RESULTS: The correlation between TMTV4.0 and TMTV41% was ρ = 0.90 for DLBCL, ρ = 0.65 for FL and ρ = 0.60 for HL. For SUVmax, SUVpeak, Dmax and Dbulk features, a strong correlation was observed with ρ > 0.95 whatever the lymphoma subtypes. The predictability of TMTV was high and comparable for the two methods with superimposable confidence intervals for the three subtypes. At the 90th percentile TMTV value, the predicted 7-year PFS was 51.13% with TMTV4.0 vs. 49.7% with TMTV41% for DLBCL patients, 45.5% vs. 39.8% for FL patients, and 82.6% vs. 80.5% for HL patients. A minority of patients showed a predicted PFS deviation > 10% between the two methods: 2.33% in DLBCL, 6.51% in FL and 1% in HL. CONCLUSION: TMTV measured with the SUV4.0 threshold provides a comparable PFS prediction than the 41%SUVmax method supporting its routine adoption particularly in the diffuse large B cell lymphoma subtype.
引用
- Malmon S, Elsensohn MH, Thieblemont C, et al. Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials. Eur J Nucl Med Mol Imaging. 2025. PMID: 40108044. doi:10.1007/s00259-025-07176-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。